Abstract：Objective To compare the effect of Pemetrexed+Cisplatin and Docetaxel+Tegiol in the treatment of advanced breast cancer.Methods All of 80 patients with breast cancer admitted to our hospital from March 2015 to July 2017 who met the inclusion criteria were retrospectively analyzed.The patients were divided into the Pemetrexed group(n=40)and Docetaxel group (n=40)according to the random number table method.Pemetrexed group was treated with Pemetrexed+Cisplatin,while Docetaxel group was treated with Docetaxel+Tegiol.The short-term efficacy,KPS score and adverse reactions in patients of the two groups were analyzed.Results Compared with before treatment,the KPS scores of both groups increased after treatment,and the differences were statistically significant(P＜0.05).There was no significant difference in KPS score between the two groups after treatment(P＞0.05).There were no significant differences in ORR and DCR between the two groups (P＞0.05).The main adverse reactions of the two groups were bone marrow suppression and gastrointestinal tract reaction,which could be alleviated after symptomatic supportive treatment.There were no significant differences in bone marrow suppression,gastrointestinal reaction,alopecia and rash classification between the two groups(Z=1.91,2.62,1.85,3.02,P＞0.05).Conclusion The clinical effect and safety of Pemetrexed+Cisplatin and Docetaxel+Tegiol in the treatment of advanced breast cancer have little difference.It can be selected according to the condition of breast cancer patients.
刘艳翠； 赵微； 孙平； 孙成. 培美曲塞+顺铂与多西紫杉醇+替吉奥治疗晚期乳腺癌的效果比较[J]. 中国当代医药, 2019, 26(17): 33-35.
LIU Yan-cui； ZHAO Wei； SUN Ping ； SUN Cheng. Effect comparison of Pemetrexed+Cisplatin and Docetaxel+Tegiol in the treatment of advanced breast cancer. 中国当代医药, 2019, 26(17): 33-35.
京公网安备 11010502046607号